Coya Therapeutics (NASDAQ: COYA) files 8-K on June 30, 2025 results

Rhea-AI Filing Summary

Coya Therapeutics, Inc. filed a current report to note that it issued a press release with information about its results of operations for the fiscal quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under the Exchange Act.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000183502200018350222025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Coya Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41583	85-4017781
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5850 San Felipe St., Suite 500
Houston, Texas				77057
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 800 587-8170

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		COYA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal quarter ended June 30, 2025. A copy of the press release is furnished under Item 2.02 of this Current Report on Form 8-K as Exhibit 99.1.

The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 7.01. Regulation FD Disclosure.

See “Item 2.02 Results of Operations and Financial Condition” above.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated August 12, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			COYA THERAPEUTICS, INC.
Date:	August 12, 2025	By:	/s/ Arun Swaminathan Ph.D.
			Arun Swaminathan Ph.D. Chief Executive Officer (Principal Executive Officer)

FAQ

What did Coya Therapeutics (COYA) disclose in this 8-K filing?

Coya Therapeutics disclosed that it issued a press release with information about its results of operations for the fiscal quarter ended June 30, 2025, and furnished that release as Exhibit 99.1 in the report.

Which period’s results are covered in Coya Therapeutics’ August 12, 2025 update?

The update covers Coya Therapeutics’ results of operations for the fiscal quarter ended June 30, 2025. Details of these results are included in the company’s press release, which is attached to the report as Exhibit 99.1.

How is the Coya Therapeutics press release treated under the Exchange Act?

The press release furnished as Exhibit 99.1 is expressly stated as not being deemed “filed” for purposes of Section 18 of the Exchange Act, limiting related liability unless it is later specifically incorporated into another company filing.

Where can investors find the detailed results mentioned by Coya Therapeutics?

Investors can find the detailed results of operations in the press release attached to the report as Exhibit 99.1. The filing explains that this exhibit contains the operational information for the quarter ended June 30, 2025.

Which items of Form 8-K does the Coya Therapeutics report address?

The report addresses Item 2.02, Results of Operations and Financial Condition, and Item 7.01, Regulation FD Disclosure. Both items reference the same press release containing information on the quarter ended June 30, 2025.

Who signed the Coya Therapeutics 8-K related to the June 30, 2025 quarter?

The report was signed on behalf of Coya Therapeutics by Arun Swaminathan, Ph.D., the company’s Chief Executive Officer and principal executive officer, dated August 12, 2025, confirming the company’s authorization of the disclosure.